Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Bicycle Therapeutics plc

Beverly Hills Institute of Ophthalmology provides ophthalmology services including LASIK surgery, cataract surgery, and comprehensive eye care. The institute is described as having advanced technology and a team of experienced ophthalmologists.

Beverly Hills Institute of Ophthalmology

Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage biopharmaceutical company focused on in-licensing, developing and commercializing oncology drug candidates in China, US, and the rest of the world.

Xynomic Pharmaceuticals Holdings, Inc.

Bicycle Therapeutics develops precision-guided therapeutics to target solid tumor cancers and other therapeutic applications. The company aims to create impactful medicines to address unaddressed medical needs.

Metric
Company Name	Bicycle Therapeutics plc	Beverly Hills Institute of Ophthalmology	Xynomic Pharmaceuticals Holdings, Inc.
Symbol	BCYC
MSH ID	COM:BICYCLETHERAPEUTICS	COM:90210EYES	COM:XYNOMICPHARMA
Market	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Medical Services	Pharmaceuticals
Country	GB	US	US
Stage			Series B
Employee Count	284
Website	bicycletherapeutics.com	90210eyes.com	xynomicpharma.com
LinkedIn
Founders

Metric
Market Cap	895.71M
Enterprise Value
Monthly Web Traffic	7.76K	1.52K
Web Traffic Growth	-0.70	4.19
Valuation
Raised Capital

Metric
Revenue	26.98M
Revenue (LTM)
Revenue (NTM)
Gross Profit	20.40M
EBITDA	-168.80M
Operating Income	-189.95M
Net Income	-180.66M
EPS	-5.08
Diluted EPS	-5.08
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.88
Operating Profit Margin	-4.32
EBITDA Margin	-6.26
Net Profit Margin	-4.04
Return on Equity	-0.33
Return on Assets	-0.16
Return on Capital Employed	-0.20

COM:BICYCLETHERAPEUTICS

Bicycle Therapeutics

Last Close

20.26

22/11 21:00

Market Cap

895.71M

Beta: -

Volume Today

284.35K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-4.18
P/B Ratio	1.62
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	47.34
EV Multiple	-7.02

Metric
Days Sales Outstanding	253.97
Days Payables Outstanding
Days Inventory Outstanding	0.00
Operating Cycle	430.51
Cash Conversion Cycle	21.28
Asset Turnover	0.08

Metric
Operating Cash Flow	-60.63M
Free Cash Flow	-63.56M
Cash Flow to Debt	-1.35
Operating Cash Flow/Sales	-2.04
Free Cash Flow Yield	-0.07

Metric
Cash & Equivalents	526.42M
Accounts Receivable	2.48M
Inventory
Goodwill
Debt to Capitalization	0.11
Debt to Assets	0.07
Current Ratio	8.65
Quick Ratio	14.77

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	1.22
R&D to Revenue	5.50
SG&A to Revenue	2.25